Mustang Bio announces targeted CAR T data for the MB-106 CD20

WORCESTER, Mass., Jan. 7, 2022 (GLOBE NEWSWIRE) – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into therapies cells and genes in potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim phase 1/2 data on MB-106, an autologous CAR T cell therapy targeted against CD20 for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma (“NHL”) and chronic lymphocytic leukemia (“CLL”), were selected for poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings ‘American Society of Transplantation and Cellular Therapy (“ASTCT”) and the Center for International Blood & Marrow Transplant Research (“CIBMTR”), which will take place February 2-6, 2022 in Salt Lake City, Uta h (“2022 Tandem Meetings”). MB-106 is being developed as part of a collaboration between Mustang and the Fred Hutchinson Cancer Research Center (“Fred Hutch”).

Manuel Litchman, MD, President and CEO of Mustang, said, “The compelling clinical activity and favorable safety profile that MB-106 continues to demonstrate in the ongoing Phase 1/2 trial in Fred Hutch demonstrate its potential as an outpatient treatment for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma and chronic lymphocytic leukemia. We look forward to the updated data that will be presented by Fred Hutch at the 2022 Tandem Meetings, particularly for patients with diffuse large B-cell lymphoma and Waldenstrom’s macroglobulinemia. We also look forward to advancing our targeted CAR T cell therapy program MB-106 CD20 to a multi-center trial as part of the IND of Mustang during the current quarter.

The details of the presentation are as follows:

Title: High efficacy and low toxicity of MB-106, a third generation CD20 targeted CAR-T for the treatment of B-NHL and relapsed / refractory CLL
Poster Number: 225
Dates and times: Thursday February 3 from 6:45 p.m. to 8:15 p.m. and Saturday February 5 from 6:15 to 7:45 p.m.
Presenter: Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutch, Seattle, WA; Physician at Seattle Cancer Care Alliance; Associate Professor, Division of Medical Oncology, University of Washington School of Medicine

For more information, please visit the Tandem Meetings 2022 website at https://na.eventscloud.com/ehome/644055/1151300/.

Note: Fred Hutch scientists played a role in the development of these discoveries, and Fred Hutch and some of his scientists may benefit financially from this work in the future.

About MB-106 (CD20 Targeted CAR T Cell Therapy)
CD20 is a membrane-integrated surface molecule that plays a role in the differentiation of B cells into plasma cells. The CAR T was developed by Mustang research collaborator Fred Hutch in the labs of the late Oliver Press, MD, Ph.D., and Brian Till, MD, associate professor in the clinical research division of Fred Hutch, and licensed exclusively from Mustang in 2017. The lentiviral vector drug substance used to transduce patient cells to create the MB-106 drug product produced at Fred Hutch has been optimized as a third generation CAR derived from fully antibody. human, and MB-106 is currently in a phase 1/2 open-label dose escalation trial in Fred Hutch in patients with B-NHL and CLL. The same lentiviral vector drug produced at Fred Hutch will be used to transduce patient cells to create the MB-106 drug product produced at Mustang Bio’s cell processing facility in Worcester, MA, for administration as part of the multicenter phase 1/2 clinical trial slated to be launched shortly as part of Mustang Bio’s IND. It should be noted that Mustang Bio made minor improvements to its cell treatment to facilitate a possible commercial launch of the product. In addition, prior to commercial launch, Mustang Bio will replace the lentiviral carrier drug substance Fred Hutch with a carrier produced by a commercial manufacturer. Additional information about the trial is available at http://www.clinicaltrials.gov using the identifier NCT03277729.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or acquiring an interest, to fund research and development, and to license or bring the technologies to market. Mustang has partnered with leading medical institutions to advance the development of CAR-T therapies for multiple cancers, as well as lentiviral gene therapies for severe combined immune deficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks linked to the results of research and development activities; risks associated with the timing of the start and end of clinical trials; uncertainties related to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our filings with the SEC. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except as required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact Person:
Tony plohoros
6 degrees
(908) 591-2839
[email protected]

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

The art of being a happy pessimist

There is a cult of “positivity” that rules the world. Through countless self-help books, banal …